Bleeding News and Research

RSS

Pfizer withdraws Bextra from market

Despite an expert panel stating last month that the three COX-2 drugs Vioxx, Bextra and Celebrex were safe enough to be marketed, the U.S. Food and Drug Administration (FDA) has this week told drug manufacturer Pfizer to remove the drug Bextra from the market and a statement by Pfizer confirms that the European Union regulators have done the same.

7 Apr 2005

Mutations in the HFE gene directly associated with chronic joint disease

Mutations in the HFE gene, which is involved in iron regulation, seem to be directly associated with chronic joint disease (or haemophilic arthropathy) among haemophilic patients, claim a team of Portuguese scientists in the April issue of the journal Blood.

4 Apr 2005

Uterine fibroid embolization is effective treatment for uterine fibroids

Data presented today at the 30th Annual Scientific Meeting of the Society of Interventional Radiology found that the nonsurgical embolization treatment for uterine fibroids had a 73 percent success rate at five years.

3 Apr 2005

First UK cases of previously rare disease reported in gay men

A previously rare disease has been reported for the first time in the UK, Lymphograunuloma venereum (LGV) is a genital/anogenital bacterial infection caused by a particularly invasive strain of Chlamydia trachomatis.

3 Apr 2005

Aspirin safer than Warfarin for treating blocked arteries

National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), have shown for the first time that aspirin works as well as warfarin in reducing blood clotting. Until now doctors have lacked good evidence for choosing one therapy over the other.

30 Mar 2005

New drug approved for treating endometriosis

Drug manufacturer Pfizer announced today that the U.S. Food and Drug Administration (FDA) has given approval for the release of depo-subQ provera 104 to be prescribed for the management of pain associated with endometriosis, a gynecological condition that affects one in ten women of reproductive age.

30 Mar 2005

Molecule that causes secondary stroke

Scientists at the University of Cincinnati (UC) College of Medicine have discovered the cause of a deadly type of secondary stroke known as cerebral vasospasm.

28 Mar 2005

Hope of new treatments for liver damage

There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

28 Mar 2005

$3.2 million for two shock-related studies

A Virginia Commonwealth University research group has been awarded $3.2 million in federal grants for two shock-related studies, one with battlefield implications and the other for emergency medicine.

21 Mar 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Aspirin use appears to reduce the incidence of colon polyps

The association between regular aspirin use and a reduced risk of precancerous colon polyps may be strongest in those with particular genetic variants.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Blood clotting combo saves heart patients lives

Two studies presented Wednesday at the American College of Cardiology's annual scientific sessions in Orlando, Fla. have found that the clot-preventing drug Plavix when added to the treatment of people with severe heart attacks helps reopen their clogged arteries and saves lives.

9 Mar 2005

Use of cilostazol, clopidogrel and aspirin results in a significant reduction of thrombotic complications in the prevention of heart attacks

Three drugs, each of which works in a different way, are used in anti-platelet therapy to help prevent restenosis (the reclogging of blood vessels after they have been cleared with percutaneous coronary intervention or PCI) or thrombosis (obstruction of an artery or vein by a blood clot).

7 Mar 2005

Aspirin does not prevent first heart attacks or death from cardiovascular causes in women

The Women's Health Study is the first large clinical trial to study the use of low-dose aspirin to prevent heart attack and stroke in women.

7 Mar 2005

Studies find Aspirin resistance in up to 27% of Aspirin users

While aspirin remains a crucial and cost-effective therapy for the prevention and management of cardiovascular diseases, research suggests that a significant percentage of the 25 million Americans on a chronic aspirin regimen are "aspirin resistant," or do not achieve sufficient antiplatelet effects from aspirin.

7 Mar 2005

First genetic marker to help identify ruptured brain aneurysm

Mayo Clinic researchers have discovered a genetic marker that may pave the way for a fast, inexpensive blood test to predict one type of deadly stroke that strikes 30,000 people in the United States annually.

6 Mar 2005

St. John's wort increases effectiveness of Plavix

The widely used herbal remedy St. John's wort appears to amplify the action of the popular blood-thinning drug clopidogrel, sold as Plavix, a small new clinical study finds.

6 Mar 2005

Researchers can now predict who will benefit from cerclage

Doctors treating pregnant women with threatened preterm birth sometimes sew the cervix closed, a procedure known as cerclage. Despite this traditional intervention, many women still lose the pregnancy.

1 Mar 2005

Genome clues to amoebic dysentery

Each year, there are an estimated 50 million cases of amoebic dysentery, causing up to 100,000 deaths, mostly in developing countries. On Thursday 24 February 2005, researchers at the Wellcome Trust Sanger Institute and their colleagues reported in Nature magazine the genome sequence of the parasite that causes the disease, Entamoeba histolytica.

1 Mar 2005